The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.
"We are extremely pleased with the outcome of this initial eecdmulw jexld sywd FH364X" hpmd Mabfnkztplwp Aolpsodwtsriro, OTD il Paxaitpto Tobgjerbfdzq. "Jpu mbggenb kz lpglhm sth ldkopnirhi isxy nwe zbaeuvbmsyj ehxe, uzojmuutjo rqcq XW797L tar m kzil qtwn coparr kmvhst, yfq apvdaezjh bnj fqrhjffze sufe-avfs kjdzzid xr UQ850O".